<DOC>
	<DOCNO>NCT01857856</DOCNO>
	<brief_summary>In Netherlands ≈15 % idiopathic dilate cardiomyopathy ( DCM ) ≈10 % arrhythmogenic right ventricular cardiomyopathy ( ARVC ) patient carry single ( founder ) mutation gene encode Phospholamban , PLN R14del . Analogous inherited cardiomyopathy , natural course disease age-related ( `` age-related penetrance '' ) ; presymptomatic phase variable length many PLN R14del-carriers progress overt disease , diagnose either DCM ARVC . PLN regulator sarcoplasmic reticulum Ca2+-ATPase ( SERCA2a ) pump cardiac muscle thereby important maintain Ca2+ homeostasis . Cardiac fibrosis appear early manifestation disease . The investigator hypothesize treatment presymptomatic PLN R14del-carriers eplerenone , virtue mineralocorticoid ( aldosterone ) -blocking property strong antifibrotic agent , reduce disease progression postpones onset overt disease .</brief_summary>
	<brief_title>PHOspholamban RElated CArdiomyopathy STudy - Intervention</brief_title>
	<detailed_description>In Netherlands ≈15 % idiopathic dilate cardiomyopathy ( DCM ) ≈10 % arrhythmogenic right ventricular cardiomyopathy ( ARVC ) patient carry single ( founder ) mutation gene encode Phospholamban , PLN R14del . Analogous inherited cardiomyopathy , natural course disease age-related ( `` age-related penetrance '' ) ; presymptomatic phase variable length many PLN R14del-carriers progress overt disease , diagnose either DCM ARVC . PLN regulator sarcoplasmic reticulum Ca2+-ATPase ( SERCA2a ) pump cardiac muscle thereby important maintain Ca2+ homeostasis . Cardiac fibrosis appear early manifestation disease . The investigator hypothesize treatment presymptomatic PLN R14del-carriers eplerenone , virtue mineralocorticoid ( aldosterone ) -blocking property strong antifibrotic agent , reduce disease progression postpones onset overt disease .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>PLN R14del mutation carrier Age ≥30 ≤ 65 year New York Heart Association functional class ≤ 1 LV ejection fraction ≥.45 ( measure MRI ) Palpitations necessitate treatment ( discretion attend physician ) A diagnosis DCM ( see appendix 1 ) . Note : regional LV wall motion abnormality acceptable . A diagnosis ARVC ( accord task force criterion , see appendix 2 ) Global regional RV dysfunction and/or structural alteration ( accord task force criterion 1 , see appendix 2 ) . Ventricular premature complex &gt; 1000 24hours Holtermonitoring Nonsustained ventricular tachycardia Holtermonitoring exercisetesting History sustain ventricular tachycardia ventricular fibrillation Hypertension require use antihypertensive drug , anticipate within come 3 year Evidence ischemic heart disease Treatment cardioactive medication Hyperkaliemia ( serum potassium &gt; 5.0 mmol/l ) Severe renal dysfunction ( eGFR &lt; 30 ml/min/1.73 m2 ) Severe hepatic impairment ( ChildPugh class C ) Women currently pregnant report recent pregnancy ( last 60 day ) plan become pregnant . Concomitant use CYP3A4inhibitors ( see appendix 5 ) Concomitant use NSAIDs ( see appendix 5 ) Concomitant use potassium highering/sparingagents ( see appendix 5 ) Known intolerance contraindication aldosterone antagonists Participation another drug trial last dose drug within past 30 day . Contraindications MRI ( claustrophobia , metal device ) Subjects unable unwilling provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Phospholamban</keyword>
	<keyword>cardiomyopathy</keyword>
	<keyword>Eplerenone</keyword>
	<keyword>presymptomatic</keyword>
</DOC>